CClinicalTrials.gg
TerminatedNCT05610969Updated May 14, 2025Results posted

Music vs Midazolam During Preop Nerve Block Placement - Part 2 Study On Anxiolytic Options Before Peripheral Nerve Blocks

A Phase 1/2 interventional study of Music and Midazolam in Peripheral Nerve Block, Anxiety and Preoperative Anxiety, sponsored by University of Pennsylvania. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by University of Pennsylvania · Phase 1/2, Interventional, and Treatment

Why this study was terminated
terminated due to lack of resources

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Sep 2021, registered Aug 2022).
Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is evaluating music vs midazolam as a means of anxiolysis for preoperative single-shot nerve block placement.

Read the detailed description

Preoperative anxiety is common and can adversely affect a patient's perioperative course by elevating stress markers, promoting fluctuations in hemodynamics and negatively impacting on postoperative recovery. Preoperative anxiety is routinely treated with pharmacologic agents such as midazolam, a benzodiazepine, which has known, undesirable side effects including respiratory depression, hemodynamic perturbations, and paradoxical effects such as hostility, aggression, and psychomotor agitation. The use of sedative medications requires continuous vital sign monitoring of patients by either anesthesia or nursing personnel and there is a question of whether midazolam helps reduce pre-procedural anxiety compared with placebo. Music is a non-pharmacologic intervention that has been shown to significantly decrease preoperative anxiety. This intervention can be used as an adjunct or even replace pharmacologic agents to help with preoperative anxiety. Music is a modality that is virtually harm-free and relatively cheap in cost. Patients who are unable to tolerate pharmacologic agents to treat preoperative anxiety can greatly benefit from non-pharmacologic options such as music.

Regional anesthesia procedures such as an ultrasound guided, peripheral nerve block is a common bedside procedure done preoperatively. Patients may have some anxiety prior to the administration of this nerve block procedure and may receive sedation for it. However, it is imperative not to over sedate them as constant feedback from the patient is necessary during the procedure. Commonly, midazolam is used to reduce this anxiety, but non-pharmacologic therapies can also reduce anxiety. In our recent published study, we evaluated the use of research-selected, relaxing music, to reduce anxiety before the nerve block is administered. In this study, we used noise-canceling headphones and played research-selected music as our anxiolytic music modality and compared this with midazolam. The findings showed no difference between both groups in the change in anxiety scores from after to before the nerve block, however patients had better satisfaction in the midazolam group and increased difficulty in communication in the music group. We attributed this to not allowing patients to choose their own selection of music and the use of noise-canceling headphones.

Therefore, in this follow-up study, we aim to evaluate the use of patient-selected music via non-noise canceling headphones as a preoperative anxiolytic prior to the administration of a bedside, peripheral nerve block procedure. This study will be conducted at an ambulatory surgical center in a university setting.

02

Conditions studied

  • Peripheral Nerve Block
  • Anxiety
  • Preoperative Anxiety

Browse trials for

Keywords

  • Midazolam
  • Adjuvants, Anesthesia
  • Anti-Anxiety Agents
  • Hypnotics and Sedatives
  • Tranquilizing Agents
  • Anesthetics
  • GABA Modulators
  • GABA Agents
  • Central Nervous System Depressants
  • Physiological Effects of Drugs
  • Neurotransmitter Agents
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 36 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,635 studies on the registry; 239 are open to participants now.

Of its 154 completed or terminated interventional studies of FDA-regulated products, 104 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who are >18 years of age
  • Patients able to give informed consent in receiving a peripheral nerve block in the preoperative bay for their primary anesthetic and/or for their postoperative pain control

Exclusion criteria

Exclusion Criteria:

  • significant psychiatric disorder such as generalized anxiety disorder, panic disorder, depression, psychosis, bipolar disorder
  • individuals who were incompetent to give informed consent
  • pregnant and/or breast-feeding patients
  • any underlying coagulopathy
  • infection or other factors which would be a contraindication to receiving a peripheral nerve block
  • hypersensitivity to midazolam
  • history of renal impairment.
  • Patients who were extremely anxious (scores greater than 50 on the State Trait Anxiety Inventory-6 (STAI-6) tool) were also excluded from the study.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Music group

    self-selected music

    Other: Music

  • Active comparator
    Midazolam group

    IV midazolam (1mg to 2mg max)

    Drug: Midazolam

Interventions

  • OtherMusic

    patients in this group will receive self-selected music after the golden moment has been completed between the patient, provider, and nursing staff

  • DrugMidazolam

    patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed

    Also known as: Hypnovel, Versed

06

What researchers measure

Primary outcomes

  1. Change in STAI-6 Scores From Post to Pre

    Spielberger State-Trait Anxiety Inventory 6 Scale range is from 20 to 80. Higher the score, the higher the anxiety level is.

    Time frame: 1-2 minutes before conducting golden moment for nerve block placement and immediately after nerve block placement (less than 1 minute after)

Secondary outcomes

  1. Patient Satisfaction Scores of the Experience During Procedure

    Survey which assess satisfaction on a 10-point numeric rating scale Scale ranges from 0 to 10. A higher number indicates a higher satisfaction

    Time frame: immediately after nerve block placement (less than 1 minute after)

  2. Provider Satisfaction Scores of the Experience During Procedure

    survey which assess satisfaction on a 10-point numeric rating scale Scale ranges from 0 to 10. A higher number indicates a higher satisfaction

    Time frame: immediately after nerve block placement (less than 1 minute after)

  3. Evaluation of Difficulties in Communication From Provider to Patient and Patient to Provider

    surveyed on a 5-point Likert scale Scale ranges from 1 to 5; the higher the number, the more difficult it is to communicate.

    Time frame: immediately after nerve block placement (less than 1 minute after)

  4. Block Times - Time it Took to do the Block

    differences amongst music and midazolam group

    Time frame: start of doing the block to immediately after nerve block placement, less than 1 minute after

07

Results

Posted May 14, 2025

Participant flow

Participant flow — Overall Study
MilestoneMusic GroupMidazolam Group
Started1521
Completed1521
Not completed00

Outcome measures

PrimaryChange in STAI-6 Scores From Post to Pre

Spielberger State-Trait Anxiety Inventory 6 Scale range is from 20 to 80. Higher the score, the higher the anxiety level is.

Time frame:
1-2 minutes before conducting golden moment for nerve block placement and immediately after nerve block placement (less than 1 minute after)
Reported as:
Mean · score on a scale
Change in STAI-6 Scores From Post to Pre
score on a scaleMusic GroupMidazolam Group
Pre STAI-634 ± 7.0235.17 ± 9.22
Post STAI-628.19 ± 5.1727.2 ± 5.00
SecondaryPatient Satisfaction Scores of the Experience During Procedure

Survey which assess satisfaction on a 10-point numeric rating scale Scale ranges from 0 to 10. A higher number indicates a higher satisfaction

Time frame:
immediately after nerve block placement (less than 1 minute after)
Reported as:
Median · units on a scale
Patient Satisfaction Scores of the Experience During Procedure
units on a scaleMusic GroupMidazolam Group
Patient Satisfaction Scores of the Experience During Procedure10 (8 to 10)9 (8 to 10)
SecondaryProvider Satisfaction Scores of the Experience During Procedure

survey which assess satisfaction on a 10-point numeric rating scale Scale ranges from 0 to 10. A higher number indicates a higher satisfaction

Time frame:
immediately after nerve block placement (less than 1 minute after)
Reported as:
Median · units on a scale
Provider Satisfaction Scores of the Experience During Procedure
units on a scaleMusic GroupMidazolam Group
Provider Satisfaction Scores of the Experience During Procedure10 (9 to 10)10 (8 to 10)
SecondaryEvaluation of Difficulties in Communication From Provider to Patient and Patient to Provider

surveyed on a 5-point Likert scale Scale ranges from 1 to 5; the higher the number, the more difficult it is to communicate.

Time frame:
immediately after nerve block placement (less than 1 minute after)
Reported as:
Median · score on a scale
Evaluation of Difficulties in Communication From Provider to Patient and Patient to Provider
score on a scaleMusic GroupMidazolam Group
Patient Perspective1 (1 to 2)1 (1 to 2)
Physician Perspective1 (1 to 2)1 (1 to 2)
SecondaryBlock Times - Time it Took to do the Block

differences amongst music and midazolam group

Time frame:
start of doing the block to immediately after nerve block placement, less than 1 minute after
Reported as:
Mean · minutes
Block Times - Time it Took to do the Block
minutesMusic GroupMidazolam Group
Block Times - Time it Took to do the Block7 ± 2.037.95 ± 3.26

Adverse events

Collected over Adverse events were noted from the beginning of the block placement up to 30 minutes after end of block placement. Due to lack of resources the study was terminated early and data collection is incomplete.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Music Group0/15 (0%)0/15 (0%)0/15 (0%)
Midazolam Group0/21 (0%)0/21 (0%)0/21 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Music GroupMidazolam GroupTotal
<=18 years000
Between 18 and 65 years142135
>=65 years101
Age, Continuous
Age, Continuous(years)Music GroupMidazolam GroupTotal
Mean42.7 ± 19.142 ± 18.142.3 ± 18.5
Sex: Female, Male
Sex: Female, Male(Participants)Music GroupMidazolam GroupTotal
Female5712
Male101424
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Music GroupMidazolam GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American459
White111526
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)Music GroupMidazolam GroupTotal
United States152136
08

Study locations

1 site
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 31, 2020
  • Informed consent form · Oct 31, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05610969
Lead sponsor
University of Pennsylvania
Responsible party
Veena Graff (Assistant Professor of Anesthesiology & Critical Care, University of Pennsylvania) — Principal investigator
First posted
Nov 9, 2022
Start date
Sep 1, 2021
Primary completion
May 8, 2023
Completion
May 8, 2023
Results posted
May 14, 2025
Last update
May 14, 2025

Study contacts

Veena Graff, MD, MS
principal investigator · University of Pennsylvania, Anesthesiology and Critical Care

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion